22 Aug 2023 • This systematic review and meta-analysis involving 44 randomized controlled trials (RCTs) aimed to explore the impact of inhaled corticosteroids (ICS) on fracture risk in chronic obstructive pulmonary disease (COPD) patients. The study included 87,594 patients and found that COPD patients receiving inhaled therapy containing ICS, particularly ICS/LABA (long-acting beta agonist) and triple therapy (ICS/LABA/long-acting muscarinic antagonist), were more likely to experience fractures compared to those receiving inhaled therapy without ICS. Specific factors such as treatment duration of 12 months or more, certain types of ICS like budesonide and fluticasone furoate, participants' mean age of 65 or older, and COPD severity stage III were associated with an increased fracture risk. Additionally, the risk of fracture varied depending on the dose and dosage form of the ICS. The study concludes that ICS inhalation therapy, particularly in combination with other drugs, is linked to a higher fracture risk in COPD patients, with various factors influencing this association. Source: BMC | Read full story